The companies expect the deal to close in the fourth quarter. MyoKardia's lead drug candidate is mavacamten, which it is developing for hypertrophic cardiomyopathy and plans to submit to the FDA in the first quarter of next year.
Bay Area startup MyoKardia just filed for an IPO with the SEC for its precision medicine approach to genetic heart disease. Specifically, it's developing small molecule drugs to treat cardiomyopathies.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
San Francisco startup MyoKardia just closed a $46 million Series B for its precision medicine approach to genetic heart disease. The startup’s studying the genetic root cause of hypertrophic and dilated cardiomyopathies – defects which result in the thickening or weakening off heart tissues, respectively. The funding will help advance its lead drug candidate, MYK-461, which is in […]